Combination Formulations And Methods For Treating Severe Metabolic Disease

Patent Status

Patent Pending

Brief Description

Obesity is a complex disorder as illustrated by the heterogenous manifestations as well as serving as a major risk factor for a plethora of related conditions including, but not limited to, hyperglycemia, hypertension, cardiovascular disease, hyperlipidemia, arthritis, gallbladder disease, sleep apnea, chronic back pain, and respiratory dysfunction. There are currently no FDA-approved therapies to address multiple conditions associated with obesity other the long term as well as no approved therapies to address specific manifestations of severe metabolic disease such as metabolic dysfunction-associated fatty liver disease (MAFLD) and steatohepatitis (MASH). Combination therapies utilizing multi- targeting agents with favorable benefit-risk profiles are in need for optimal disease modification.

UCB researchers have discovered methods for treating severe metabolic diseases by simultaneously or sequentially administering to an individual an effective amount of a therapeutic compound and at least one metabolism modifier having dual agonism or tri-agonism activity.

Suggested uses

• treatment of metabolic dysfunction-associated fatty liver disease (MAFLD) and steatohepatitis (MASH)